Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Diazepam
Therapeutic Area : Neurology
Study Phase : Approved FDF
Recipient : Aquestive Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Details : Under the expanded agreement, Pharmanovia will cover the Additional Global Markets for Libervant™ (diazepam) buccal film, a benzodiazepine intended for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity.
Product Name : Libervant
Product Type : Controlled Substance
Upfront Cash : Undisclosed
March 29, 2023
Lead Product(s) : Diazepam
Therapeutic Area : Neurology
Highest Development Status : Approved FDF
Recipient : Aquestive Therapeutics
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Approved FDF
Recipient : AstraZeneca
Deal Size : $390.0 million
Deal Type : Divestment
AstraZeneca divests rights to established hypertension medicines
Details : AstraZeneca is seeking $350 million from Atnahs Pharma for global trade rights to a series of five hypertension drugs off-patent: Inderal, Tenormin, Tenoretic, Zestril and Zestoretic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : $350.0 million
January 27, 2020
Lead Product(s) : Propranolol Hydrochloride
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Approved FDF
Recipient : AstraZeneca
Deal Size : $390.0 million
Deal Type : Divestment
Reset All
